Volition Launches Nu.Q Vet Cancer Screening Test in the US and in Europe Through Heska
VolitionRx, a multi-national epigenetics company, has launched its Nu.Q® Vet Cancer Screening Test across the US and the forthcoming launch in Europe by Heska Corporation, a leading global provider of advanced veterinary diagnostics, through Heska’s veterinary diagnostic laboratories.
Steve Eyl, Heska’s Chief Commercial Officer and President, scil animal company, said, “Our team has been working closely with Volition throughout the past six months and we are delighted to launch Volition’s Nu.Q Vet Cancer Screening Test in the US and announce the forthcoming launch in Europe expected in the coming weeks through our veterinary diagnostics laboratories. The accurate, affordable and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska’s expanding portfolio of best-in-class solutions. This is an important achievement in our transformative work together as we move towards the launch of our flagship point of care solution anticipated in 2023.”
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said, “We’re thrilled to be working alongside Heska and support the launch of the Nu.Q Vet Cancer Screening Test in the United States and Europe. It is another key milestone for us, as we press ahead with our aim to ensure as many veterinarians as possible can access our Nu.Q Vet Cancer Screening Test for the pets and pet owners who trust them. There are approximately 84 million pet dogs in the United States and approximately half of dogs will have at least one veterinary care visit each year. Implementing the Nu.Q Vet Cancer Screening Test at annual wellness visits can help detect cancer at an early stage, even before symptoms appear, allowing for a better chance of effective treatment and improved outcomes.”
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q technology, click here.